STOCK TITAN
  1. Home
  2. Sec-filings
  3. BMY
  4. [Form 4] BRISTOL MYERS SQUIBB CO Insider Trading Activity

Bristol Myers (NYSE: BMY) director receives grant of deferred share units

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Bristol Myers Squibb director Michael R. McMullen received a grant of 607.428 Deferred Share Units, each valued at $57.62. These units represent deferred compensation that will be converted into common stock when he ceases to be a director or at a previously chosen future date.

Following this award, McMullen holds a total of 16,332.540 Deferred Share Units tied to Bristol Myers Squibb common stock, including prior deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. This filing reflects a compensation-related equity award rather than an open-market stock purchase or sale.

Positive

  • None.

Negative

  • None.
Insider McMullen Michael R.
Role null
Type Security Shares Price Value
Grant/Award Deferred Share Units 607.428 $57.62 $35K
Holdings After Transaction: Deferred Share Units — 16,332.54 shares (Direct, null)
Footnotes (1)
  1. Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Deferred Share Units granted 607.428 units Grant of Deferred Share Units on 2026-06-30
Grant reference price $57.62 per unit Value per Deferred Share Unit for this award
Total Deferred Share Units held 16,332.540 units Holdings following the reported transaction
Underlying common stock 607.428 shares Common stock underlying the new Deferred Share Units
Conversion price $0.00 Conversion or exercise price of Deferred Share Units
Deferred Share Units financial
"Each Deferred Share Unit will be converted into a share of common stock upon settlement."
Deferred share units are promises that give an executive or director the right to receive company shares or their cash value at a future date, often when they retire or leave the company. Think of them as a paycheck held in a savings account that converts into stock later; they matter to investors because they tie pay to long-term performance, create potential future dilution of shares, and represent a delayed cash or share obligation the company must eventually fulfill.
deferred compensation financial
"Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors."
Deferred compensation is pay that employees or executives have earned now but will receive at a later date, such as delayed bonuses, retirement benefits, or stock grants. It matters to investors because it creates future obligations and shapes incentives—like a promise to pay later that can affect a company’s reported profits, cash needs and potential stock dilution—so it helps signal how a business manages costs and retains key people.
1987 Deferred Compensation Plan for Non-Employee Directors financial
"Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors."
dividends reinvested financial
"Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
McMullen Michael R.
(Last)(First)(Middle)
BRISTOL-MYERS SQUIBB COMPANY
ROUTE 206 AND PROVINCE LINE ROAD
(Street)
PRINCETON NEW JERSEY 08543
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
BRISTOL MYERS SQUIBB CO [ BMY ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Deferred Share Units(1)06/30/2026A607.428 (1) (1)Common Stock, $0.10 par value607.428$57.6216,332.54(2)D
Explanation of Responses:
1. Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
2. Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Remarks:
/s/ Amy Fallone, attorney-in-fact for Michael R. McMullen07/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Bristol Myers Squibb (BMY) director Michael R. McMullen report in this Form 4?

Michael R. McMullen reported receiving 607.428 Deferred Share Units as a compensation-related award. Each unit is valued at $57.62 and represents a right to receive Bristol Myers Squibb common stock in the future, rather than an immediate stock market transaction.

How many Deferred Share Units does BMY director Michael R. McMullen hold after this award?

After the award, Michael R. McMullen holds 16,332.540 Deferred Share Units. This total includes the new 607.428-unit grant plus previously accrued deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors at Bristol Myers Squibb.

When will Michael R. McMullen’s Bristol Myers Squibb Deferred Share Units be settled into common stock?

Each Deferred Share Unit will convert into one share of Bristol Myers Squibb common stock upon settlement. The units become settleable when McMullen ceases to be a director or at a future date he previously specified under the company’s non-employee director compensation plan.

Is Michael R. McMullen’s Form 4 transaction in BMY stock a market buy or sell?

The reported transaction is not a market buy or sell. It is a grant of 607.428 Deferred Share Units as compensation. These derivative units convert into common stock later and do not reflect an open-market purchase or sale of Bristol Myers Squibb shares.

What is the value per unit of Michael R. McMullen’s new Deferred Share Units in BMY?

Each of the 607.428 newly granted Deferred Share Units is valued at $57.62. This amount reflects the reference price used for the award, linking the units’ economic value to Bristol Myers Squibb’s common stock for the director’s deferred compensation.